LC15-0444 + pioglitazone

This drug is a **combination therapy** comprising LC15-0444 (gemigliptin) and pioglitazone, both orally administered agents used for the management of type 2 diabetes mellitus. **LC15-0444 (gemigliptin)** is a selective and competitive inhibitor of dipeptidyl peptidase-4 (DPP-4), which increases levels of active glucagon-like peptide-1 (GLP-1), thereby enhancing insulin secretion and reducing postprandial glucose. **Pioglitazone** is a thiazolidinedione that acts as an agonist of peroxisome proliferator-activated receptor gamma (PPARγ), improving insulin sensitivity in adipose tissue, skeletal muscle, and the liver. The combination is intended to provide complementary glucose-lowering effects by targeting both insulin resistance (pioglitazone) and enhancing incretin effects (LC15-0444)[1][2][6].

Brand names

Actos

Other names

gemigliptin